OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma
Status:
Completed
Trial end date:
2020-05-21
Target enrollment:
Participant gender:
Summary
This is an exploratory Phase I study is to assess the safety and tolerability of the OXIRI
regimen [oxaliplatin (O), xeloda (X) and irinotecan (I)] and to evaluate for preliminary
evidence of efficacy, in patients with advanced and/or metastatic pancreatic adenocarcinoma.
The investigators hypothesize that 2 of 3 weekly doses of oxaliplatin and genotype
directed-dosing of irinotecan in combination with chronomodulated capecitabine (xeloda)
administered continuously will be more tolerable than the FOLFIRINOX regimen (folinic acid,
fluorouracil, irinotecan and oxaliplatin) while maintaining anti-tumour activity.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Centre, Singapore
Collaborator:
National Medical Research Council (NMRC), Singapore